within Pharmacolibrary.Drugs.ATC.B;

model B03AA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.87 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 325 / 1000000,
    adminCount     = 1,
    Vd             = 0.008,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Ferrous gluconate is an iron salt used to treat or prevent iron deficiency anemia. It is an orally administered iron supplement commonly used for patients with low iron levels. It is an approved drug by regulatory agencies and is in clinical use today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult individuals after oral administration. No direct human publication reporting full compartmental PK parameters found; values estimated from related iron oral supplements and general iron pharmacokinetic knowledge.</p><h4>References</h4><ol><li><p>Lausević, M, et al., &amp; Stojimirović, B (2006). [Resorption and tolerance of the high doses of ferrous sulfate and ferrous gluconate in the patients on peritoneal dialysis]. <i>Vojnosanitetski pregled</i> 63(2) 143–147. DOI:<a href=&quot;https://doi.org/10.2298/vsp0602143l&quot;>10.2298/vsp0602143l</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16502988/&quot;>https://pubmed.ncbi.nlm.nih.gov/16502988</a></p></li><li><p>Lysionek, AE, et al., &amp; Boccio, JR (2003). Stabilized ferrous gluconate as iron source for food fortification: bioavailability and toxicity studies in rats. <i>Biological trace element research</i> 94(1) 73–78. DOI:<a href=&quot;https://doi.org/10.1385/BTER:94:1:73&quot;>10.1385/BTER:94:1:73</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12907829/&quot;>https://pubmed.ncbi.nlm.nih.gov/12907829</a></p></li><li><p>Campbell, N, et al., &amp; Sundaram, R (1988). Alteration of methyldopa absorption, metabolism, and blood pressure control caused by ferrous sulfate and ferrous gluconate. <i>Clinical pharmacology and therapeutics</i> 43(4) 381–386. DOI:<a href=&quot;https://doi.org/10.1038/clpt.1988.47&quot;>10.1038/clpt.1988.47</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3356082/&quot;>https://pubmed.ncbi.nlm.nih.gov/3356082</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B03AA03;
